Nanjing Immunophage Biomedical

Immunophage Biomedical is a clinical-stage biopharmaceutical company based in Nanjing, China, dedicated to the discovery and development of innovative small molecule drugs for cancer and autoimmune diseases. The company focuses on modulating the tumor microenvironment and immune signaling pathways to address unmet medical needs in oncology. Its lead clinical candidate, IPG1094, is a selective EP4 receptor antagonist designed to enhance anti-tumor immunity, currently in Phase 1/2 trials. Additionally, the company is advancing IPG7236, a potent HPK1 inhibitor, through early-stage clinical development. Immunophage leverages its proprietary drug discovery platform and a team of experienced scientists to build a robust pipeline of first-in-class and best-in-class therapeutics.